This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
SurfingMASH concludes its coverage of the Emerging Trends Conference looking at an encouraging future in MASLD drug development and increasing interest in patient advocacy.
This week’s expert interview with Jeff McIntyre of the Global Liver Institute took place one day after news media reported on high-level job cuts at FDA. Jeff and Roger discuss possible implications for MASH drug and diagnostic development and the steps patients can take to protect their rights and health.
This week’s Roundtable segment focuses on what we can learn from today’s trial results about trends for the future and asks questions about ALD trial design.
This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for #TLM2025.
This conversation focuses on two patient-related issues: the importance of patient advocacy in removing biopsy from clinical trial designs and more generally, principles for patient-centric clinical trials.
This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the “FDA Corner” session.
In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide’s Phase 3 trial demonstrating regression of fibrosis.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
